title: The influence of perinatal infective factors on ophthalmia neonatorum.
abstract: BACKGROUND
  Ophthalmia neonatorum still blinds approximately 10,000 babies annually worldwide. Identification of contributory maternal perinatal factors could possibly predict which babies are at greater risk for this disease.
  
  
  METHODS
  In a randomized prospective study of ophthalmia neonatorum in Kenya, we studied the effect of prophylaxis with povidone-iodine, silver nitrate, and erythromycin in 3117 neonates. Four perinatal factors that may promote ophthalmia neonatorum were investigated: maternal vaginitis, birth in a nonsterile environment, presence of meconium at birth, and postnatal development of endometritis.
  
  
  RESULTS
  No significant difference in the general ophthalmia neonatorum rate was found for any of the four factors (P > .14 by Fisher exact test). However, with regard to venereal ophthalmia neonatorum, the 26 infants born to mothers with vaginitis had a relative risk 5.1 times that of the rest of the infants (P = 0.0013). Their relative risk to develop gonococcal ophthalmia neonatorum in particular was 24.9 times the rest of the neonates (P = 0.0000031). Prophylaxis was with povidone-iodine in 12 infants, silver nitrate in two, and erythromycin in 12. The frequency of ophthalmia neonatorum was 25%, 100%, and 33%, respectively (differences not significant).
  
  
  CONCLUSIONS
  Neonates born to mothers with vaginitis should be carefully observed for the first postnatal month for the development of ophthalmia neonatorum, even though a prophylactic agent has been used.
authors.affiliation: Department of Ophthalmology, Harbor-UCLA Medical Center, UCLA School of Medicine 90095-7001, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Isenberg
authors.forename: L
authors.initials: L
authors.lastname: Apt
authors.forename: M
authors.initials: M
authors.lastname: Wood
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D004716:Endometritis / Q000150:complications*; D004917:Erythromycin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007630:Kenya / Q000453:epidemiology; D018811:Maternal Exposure; D008470:Meconium; D009878:Ophthalmia Neonatorum / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D011206:Povidone-Iodine / Q000627:therapeutic use; D015995:Prevalence; D011446:Prospective Studies; D012189:Retrospective Studies; D012307:Risk Factors; D012835:Silver Nitrate / Q000627:therapeutic use; D014627:Vaginitis / Q000150:complications*
chemical_list: D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D004917:Erythromycin; D011206:Povidone-Iodine; D012835:Silver Nitrate